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Summary
INTRODUCTION: Sudden cardiac death caused by ma-
lignant arrhythmia can be prevented by the use of de-
fibrillators. Although the wearable cardioverter defibrillator
(WCD) can prevent such an event, its role in clinical prac-
tice is ill defined. We investigated the use of the WCD in
Switzerland with emphasis on prescription rate, therapy
adherence and treatment rate.
MATERIALS AND METHODS: The Swiss WCD Registry
is a retrospective observational registry including patients
using a WCD. Patients were included from the first WCD
use in Switzerland until February 2018. Baseline charac-
teristics and data on WCD usage were examined for the
total study population, and separately for each hospital.
RESULTS: From 1 December 2011 to 18 February 2018,
a total of 456 patients (67.1% of all WCDs prescribed in
Switzerland and 81.1% of all prescribed in the participating
hospitals) were included in the registry. Up to 2017 there
was a yearly increase in the number of prescribed WCDs
to a maximum of 271 prescriptions per year. The mean
age of patients was 57 years (± 14), 81 (17.8%) were
female and mean left ventricular ejection fraction (EF)
was 32% (± 13). The most common indications for WCD
use were new-onset ischaemic cardiomyopathy (ICM) with
EF ≤35% (206 patients, 45.2%), new-onset nonischaemic
cardiomyopathy (NICM) with EF ≤35% (115 patients,
25.2%), unknown arrhythmic risk (83 patients, 18.2%),
bridging to implantable cardioverter-defibrillator implanta-
tion or heart transplant (37 patients, 8.1%) and congenital/
inherited heart disease (15 patients, 3.3%). Median wear
duration was 58 days (interquartile range [IQR] 31–94)
with a median average daily wear time of 22.6 hours (IQR
20–23.2). Seventeen appropriate therapies from the WCD
were delivered in the whole population (treatment rate:
3.7%) to a total of 12 patients (2.6% of all patients). The
most common underlying heart disease in patients with a
treatment was ICM (13/17, 76.5%). There were no inap-
propriate treatments.
CONCLUSION: The use of WCDs has increased in
Switzerland over the years for a variety of indications.
There is high therapy adherence to the WCD, and a treat-
ment rate comparable to previously published registry da-
ta.
Keywords: wearable cardioverter defibrillator, sudden
cardiac death, implantable cardioverter-defibrillator, real-
world registry, Switzerland
Introduction
Cardiovascular mortality remains the number one cause
of death in Switzerland. Of the 66,971 persons deceased
in 2017 in Switzerland, 31.4% died from cardiovascular
causes [1]. Sudden cardiac death is a disastrous manifes-
tation of heart disease, most commonly due to malignant
arrhythmia. After the first successful implantation of an
implantable cardioverter defibrillator (ICD) in 1980, the
ICD has established itself in the early 2000s after several
landmark studies for secondary and primary prevention of
SCD in patients with severely impaired left ventricular sys-
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tolic function (EF). The wearable cardioverter defibrillator
(WCD), however, emerged later. Auricchio and colleagues
first demonstrated its clinical efficacy in the treatment of
malignant arrhythmias such as ventricular fibrillation and
tachycardia (VF and VT) [2].
In Switzerland, off-label WCD use began in 2011, and was
officially approved in 2014 [3]. Current reimbursement in
Switzerland is generally for 30 days with the possibility of
an extension upon request. Its use is accepted, as in current
European guidelines, for temporary protection from sud-
den cardiac death in selected patients [4, 5]. Despite one
randomised controlled trial and several registries investi-
gating the use of the WCD, questions remain regarding its
true benefit and patterns of use.
The aim of the Swiss WCD Registry is to provide infor-
mation on the prescription practices and outcome of pa-
tients with WCD in Switzerland and to put these into con-
text with previously published data.
Material and methods
Swiss WCD Registry
The Swiss WCD Registry is a multicentre, retrospective
observational registry including 12 hospitals prescribing
WCDs in Switzerland. The WCD (LifeVest, ZOLL, Pitts-
burgh, Pennsylvania, USA) has previously been described
[6, 7]. Participating hospitals are University Hospital
Zurich (USZ), University Hospital Basel (USB), Universi-
ty Hospital Bern (Inselspital), University Hospital Geneva
(HUG), University Hospital Lausanne (CHUV), Cantonal
Hospital Winterthur (KSW), Cantonal Hospital St Gallen
(KSSG), Triemli Hospital Zurich (Triemli), Cantonal Hos-
pital Lucerne (LUKS), Cantonal Hospital Aarau (KSA),
Cantonal Hospital Graubünden (KSGR), and GZO Re-
gional Healthcare Centre Wetzikon (GZO). The observa-
tion period was between the time of the approval and first
prescription of a WCD in Switzerland, December 2011,
and February 2018. All patients with WCD use were in-
cluded. Patients who refused to participate or patients with
incomplete data, including those patients still wearing the
WCD, were excluded. The study was approved by the re-
sponsible ethics committee and conforms to the Declara-
tion of Helsinki as revised in 2013.
Baseline characteristics and outcome data were collected
from the respective electronic patient charts of each hos-
pital using REDCap Software (Vanderbilt, Nashville, TN,
USA). WCD prescription practices for all patients (includ-
ing the patients treated at the 12 hospitals) in Switzer-
land was provided by the manufacturer ZOLL. Patient-lev-
el WCD data from the LifeVest Network (average daily
wear-time, automatic recordings, etc.) were available to
all treating physicians; the manufacturer, however, provid-
ed a comprehensive pseudonymised database. Underlying
heart disease was categorised as ischaemic cardiomyopa-
thy (ICM), nonischaemic cardiomyopathy (NICM) and in-
herited/congenital heart disease according the final diag-
nosis at each institution. Indications for WCD use were
categorised as follows [6]:
– Existing ICD indication and bridging due to ICD infec-
tion or infection at the time of planned ICD implanta-
tion, bridging to planned heart transplantation or bridg-
ing for other reasons (“bridging”).
– New-onset heart failure due to ICM with an EF ≤35%
after myocardial infarction (MI), percutaneous coro-
nary intervention (PCI) and/or coronary artery bypass
graft surgery (CABG).
– New-onset heart failure due to NICM with an EF ≤35%.
– New-onset heart failure due to congenital/inherited
heart disease with an EF ≤ 35%.
– Unknown arrhythmic risk for patients felt to be at high
risk for sudden cardiac death, in particular syncope of
unknown aetiology.
The yearly prescription of WCD since its first use in
Switzerland was provided by the manufacturer. No further
involvement of the manufacturer in data collection, statis-
tical analysis or writing of the manuscript took place.
Statistical analysis
A descriptive statistical analysis was performed on the
available data set. Categorical variables are reported as fre-
quencies (percentage), continuous variables as means (±
standard deviation) or as medians (IQR, range). The fol-
low-up time was also calculated in person-months (number
of patients multiplied by the mean wear duration in days
for the total study population divided by 30.4 – the calcu-
lated average length of a month). The incident appropriate
treatment rate (or treatment incidence) was calculated as
treatments/person-months and multiplied by three to pro-
vide 3-month rate, as previously described [8]. Prolonged
WCD use was separately analysed. Exploratory statistical
analysis was performed by comparing continuous data us-
ing Student’s t-test, the Mann-Whitney U-test or Kruskal-
Wallis test as appropriate depending on data distribution
and number of samples compared. Categorical data was
analysed using the chi-square test. Correlation was cal-
culated using Pearson’s coefficient. A two-sided p-value
<0.05 was considered statistically significant. All statisti-
cal analyses were conducted using SPSS version 25 (IBM
Corp., Armonk, NY, USA). This study was conducted ac-
cording to the STROBE statement.
Results
Prescription in Switzerland
Between 1 December 2011 and 18 February 2018, 28 pre-
scribing healthcare centres (hospitals and private cardiolo-
gy practices) prescribed a WCD for a total of 679 patients
in Switzerland. The yearly prescription rate rose signifi-
cantly from its first use in 2010 after its approval by the
MiGeL and increased yearly until the end of the study pe-
riod. The highest prescription rate was in 2017 (fig. 1). The
highest monthly prescription rate was 34 in one month in
May 2017.
Baseline characteristics and prescription practices
Of all patients, 562 (82.7%) were prescribed a WCD at one
of the 12 participating hospitals. After applying the exclu-
sion criteria, 456 patients (81.1% of all patients at partic-
ipating hospitals) were included in the Swiss WCD Reg-
istry (fig. 2). Baseline characteristics were available for all
included patients (n = 456, table 1).
The mean age in the total study population was 57 years
(± 14), 81 patients (17.8%) were female, mean body mass
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index at therapy start was 26.9 kg/m2 (± 5.8) and mean EF
at therapy start was 32% (± 13). Atrial fibrillation was di-
agnosed prior to therapy in 108 patients (24.7%). The most
common indications for WCD use were ICM with an EF
≤35% (206 patients, 45.2%), NICM with an EF ≤35% (115
patients, 25.2%), unknown arrhythmic risk (83 patients,
18.2%), bridging to ICD implantation or heart transplant
(37 patients, 8.1%) and congenital/inherited heart disease
(15 patients, 3.3%). After exploratory analysis, significant
differences among prescribing hospitals were found in
gender distribution, baseline EF and the proportion of pa-
tients treated with a mineralocorticoid antagonists (MRA).
This difference for the use of MRA significantly when pa-
tients with an EF ≤35% were compared (p = 0.003).
Adherence and wear duration
The median wear duration in the total study population
was 58 days (IQR 31–94, range 1–455) with a median av-
erage daily wear-time of 22.6 hours (IQR 20–23.2, range
0.7–23.8). This observational period sums up to a total
of 1005 person-months (table 2). Overall, 217 patients
(47.6%) had a wear duration longer than 60 days.
Treatment rate and incidence
A total of 17 WCD treatments were administered in the
total population (treatment rate 3.7%) to a total of 12 pa-
tients (2.6% of all patients). The incident appropriate treat-
ment rate per 3 months in the total study population was 5
events per 100 persons over a 3-month wear duration. The
Table 1: Baseline characteristics of the study population.
Hospital USZ USB KSW HUG KSSG Triemli CHUV KSA Inselspital GZO LUKS KSGR
Number* 192 (42) 43 (9) 38 (8) 33 (7) 27 (6) 26 (6) 22 (5) 21 (5) 20 (5) 15 (3) 13 (3) 6 (1)
Age (years) 58 ± 13 58 ± 14 60 ± 17 59 ± 14 54 ± 15 59 ± 12 58 ± 14 52 ± 15 50 ± 17 62 ± 14 53 ± 12 51 ± 15
Female* 26 (14) 5 (12) 7 (18) 5 (15) 7 (26) 3 (12) 10 (46) 6 (29) 5 (25) 3 (20) 3 (23) 1 (17)
BMI (kg/m2) 27 ± 6 27 ± 5 26 ± 3 25 ± 4 27 ± 6 26 ± 4 26 ± 8 26 ± 5 25 ± 4 28 ± 6 27 ± 6 26 ± 2
EF before WCD use (%)* 32 ± 13 27 ± 11 31 ± 15 29 ± 13 33 ± 16 29 ± 10 36 ± 17 34 ± 10 33 ± 14 32 ± 7 33 ± 15 38 ± 12
Atrial fibrillation 55 (29) 12 (28) 9 (28) 6 (18) 4 (15) 8 (31) 2 (9) 2 (10) 4 (20) 4 (28) 2 (15) 0 (0)
Indication
– ICM (LVEF <35%) 82 (43) 22 (51) 17 (45) 14 (42) 12 (44) 17 (65) 8 (36) 11 (52) 10 (50) 8 (53) 3 (23) 2 (33)
– NICM (LVEF <35%) 53 (27) 9 (21) 13 (34) 13 (40) 7 (26) 5 (19) 4 (18) 2 (10) 1 (5) 2 (13) 5 (38) 1 (17)
– Congenital/inherited heart
disease
7 (4) 0 (0) 1 (3) 1 (3) 2 (7) 1 (4) 2 (9) 0 (0) 1 (5) 0 (0) 0 (0) 0 (0)
– Bridging to ICD implant or
HTX
18 (9) 6 (14) 0 (0) 1 (3) 1 (4) 1 (4) 3 (14) 1 (5) 5 (25) 0 (0) 1 (8) 0 (0)
– Unknown arrhythmic risk 32 (17) 6 (14) 7 (18) 4 (12) 5 (19) 2 (8) 5 (23) 7 (33) 3 (15) 5 (34) 4 (31) 3 (50)
Baseline medication
– Beta-blocker 170 (89) 39 (91) 36 (95) 30 (91) 23 (85) 24 (92) 22 (100) 21 (100) 18 (90) 15 (100) 10 (77) 6 (100)
– ACEI/ATIIB/
Sacubitril/valsartan
169 (88) 40 (93) 33 (87) 27 (82) 22 (82) 24 (92) 15 (68) 20 (95) 18 (90) 15 (100) 11 (85) 6 (100)
– Aldosterone
antagonist*
105 (55) 34 (79) 25 (66) 16 (49) 13 (48) 23 (89) 14 (64) 13 (62) 12 (60) 9 (60) 10 (77) 5 (83)
– Amiodarone 43 (22) 6 (14) 3 (8) 6 (18) 6 (22) 6 (23) 0 (0) 2 (10) 4 (20) 2 (13) 2 (15) 0 (0)
EF = ejection fraction; ICM = ischaemic heart disease; NICM = nonischaemic heart disease; HTX = heart transplant; ACEI = ACE inhibitor; ATIIB = angiotensin II receptor antag-
onist. Results are reported as frequencies (percentage) or mean ± standard deviation. * Significant difference between prescribing hospitals detected (p <0.05).
Table 2: Wearable cardioverter defibrillator (WCD) data for the study population.
Hospital USZ USB KSW HUG KSSG Triemli CHUV KSA Inselspital GZO LUKS KSGR
Number 192 (42) 43 (9) 38 (8) 33 (7) 27 (6) 26 (6) 22 (5) 21 (5) 20 (5) 15 (3) 13 (3) 6 (1)
Wear duration (days,
IQR)
63
(35–98)
71
(18–99)
54
(28–94)
40
(23–57)
42
(15–99)
73
(38–101)
44
(21–89)
76
(45–94)
47
(18–84)
57
(41–85)
77
(50–100)
43
(10–69)
Average daily wear
hours (IQR)
22.6
(19.8–23.2)
22.8
(19.8–23.4)
22.6
(18.2–23.3)
22.5
(19.7–23.1)
22.3
(20.6–23.3)
22.6
(20.8–23.3)
22.4
(21.4–22.9)
22.9
(19.9–23.2)
22.3
(18.3–23.1)
22.8
(22–23.1)
22.5
(21–23.3)
21
(17–23.2)
Person-months 423.2 94.8 83.8 72.7 59.5 57.3 48.5 46.3 44.1 33.1 28.7 13.2
Total
WCD treatments
3 4 0 0 2 0 2 0 4 0 0 2
WCD treatments (%) 3 (1.6) 3 (7) 0 (0) 0 (0) 1 (3.7) 0 (0) 1 (4.5) 0 (0) 3 (15) 0 (0) 0 (0) 1 (16.7)
Treatment incidence per
3 person-months
2.13 12.66 0 0 10.08 0 12.37 0 27.22 0 0 45.37
Results are reported as frequencies (percentage).
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range of treatment incidence among the participating hos-
pitals was 0 (50% of all participating hospitals) to 45.37
(table 2). Five patients each received two treatments by
the WCD. All delivered treatments were appropriate; there
were no inappropriate treatments during the study period
(table 3).
Figure 1: Prescription of the wearable cardioverter defibrillator in
Switzerland 2010–2017.
Figure 2: Flow chart of the study population.
Thirteen treatments (13/17, 76.5%) were delivered to pa-
tients with ICM and EF ≤35%, three treatments (3/17,
17.7%) to patients waiting for ICD implantation or heart
transplantation (“bridging”) and one treatment to a patient
suffering from NICM with EF ≤35% (1/17, 5.9%). The
incident appropriate treatment rate per 100 persons per 3
months was 8.6, 11 and 1.2 for ICM, bridging and NICM,
respectively. The mean age of patients with treatments was
63 years old (± 11), 2 of the patients were female (16.7%),
they had a mean EF of 24% (± 5) and wore the device for a
median of 16 days (IQR 8–39) with an average daily wear
time of 22.1 hours (IQR 19.1–22.7). The clinical character-
istics of patients with treatments varied among prescribing
hospitals (table 3). There was no significant difference be-
tween with and without treatments in any of the baseline
characteristics including the rate of prior myocardial in-
farction, any type of revascularisation (percutaneous coro-
nary intervention of aorto-coronary bypass surgery) and
coexisting moderate to severe valvulopathy (table S1 in ap-
pendix 1).
Of the total study population, 271 patients (47.6%) had a
prolonged WCD use (>60 days). There was no significant
difference in the rate of prolonged WCD use between hos-
pitals, ranging from 21% (HUG) to 61.5% (LUKS). Of
the 12 patients receiving treatments two wore the device
longer than 60 days (72 and 79 days).
ICD implantation rate after end of WCD use
After discontinuation of WCD use, 212 patients (46.5% of
the total study population) were implanted with an ICD,
whereas 183 patients (40.1%) no longer had an indication
for ICD implantation due to either improvement in EF, dis-
appearance of elevated arrhythmic risk or other reasons
(table 4). The remaining patients either refused ICD im-
plantation (20 patients, 4.4%), or had other reasons for no
ICD implantation such as end-of-life care, unknown rea-
sons (37 patients, 8.1%), or loss to follow-up (4 patients,
0.8%).
Table 3: Patients with treatments by the wearable cardioverter defibrillator.
Patient 1 2 3 4 5 6 7 8 9 10 11 12
Hospital USZ USZ CHUV Inselspital Inselspital Inselspital KSGR KSSG USB USB USZ USB
Age (years) 71 60 57 53 63 71 46 74 66 82 64 47
Sex Male Male Female Male Male Male Male Male Female Male Male Male
EF before WCD
(%)
27 13 28 35 25 20 25 22 22 25 25 20
Indication for
WCD
Bridging NICM ICM ICM ICM ICM ICM ICM ICM Bridging Bridging ICM
Atrial fibrillation No Yes No No Yes No No Yes No No No No
Wear days 18 72 15 11 14 38 2 5 5 79 40 17
Average wear
hours
20.18 23.1 22.66 21.91 17.78 22.78 10.77 18.61 19.56 23.38 22.28 22.42
Treatments by
WCD (n)
1 1 2 1 2 1 2 2 1 1 1 2
Treated arrhyth-
mia
VT VF VT, VT VT VT, VT VF VT, VF VT, VT VT VT VT VF, VF
Device implanted S-ICD CRT-D SC-ICD DC-ICD DC-ICD SC-ICD SC-ICD SC-ICD SC-ICD DC-ICD SC-ICD SC-ICD
First ICD therapy
after implantation
Appropriate
shock
none Appropriate
ATP
Appropriate
shock
none Appropriate
shock
none none none none none none
CRT = cardiac resynchronisation therapy; DC = dual-chamber; EF = ejection fraction; ICM = ischaemic cardiomyopathy; NICM = nonischaemic cardiomyopathy; S = subcuta-
neous; SC = single-chamber; WCD = wearable cardioverter defibrillator; VF = ventricular fibrillation; VT = ventricular tachycardia
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Discussion
The WCD has established itself throughout Switzerland
for prevention of sudden cardiac death in patients per-
ceived to be at high risk. In this study, for the first time we
describe the patient population using the complete Swiss
WCD Registry.
We report an incident appropriate treatment rate for the to-
tal Swiss WCD population of 5 per 100 persons over 3
months. In a meta-analysis, Masri et al. investigated dif-
ferences in treatment incidences between all studies re-
porting WCD treatments [8]. They reported a pooled inci-
dence from all included studies of 5 per 100 persons over
3 months, similar to our findings. They noted, however,
a large range in treatment incidences and also significant
heterogeneity among the included studies regarding study
population size and indications for WCD use. We similarly
found a large variance for treatment incidence in the hos-
pitals included in our study. This variance could be attrib-
uted to the different, and in some cases low, patient num-
bers leading to frequent numerical outliers, which make the
use of deductive statistical analysis impractical. USZ, the
hospital with the highest number of WCD prescriptions,
reported a low treatment incidence in comparison with the
other prescribing hospitals with at least one treatment. Of
note, no patients with ICM received a treatment in this sub-
population. Although there was a significant difference in
EF in the included centres, the overall guideline-oriented
heart failure therapy was established in the vast majority of
the total study population without relevant variations be-
tween participating centres. Ultimately, no significant dif-
ference in any baseline characteristics of patients treated
at USZ as compared with all other hospitals explained this
difference in treatment incidence.
The significantly higher baseline EF may partially explain
the lower treatment incidence observed at USZ compared
with other prescribing hospitals with at least one treatment,
since in particular patients suffering from ICM with lower
EF seemed to benefit more from an ICD, and no patient
suffering from ICM received a treatment by the WCD in
the USZ subpopulation [9, 10]. Of note, the average LVEF
at USZ for this subpopulation was 32% (± 13), which was,
however, still higher than the 28% (± 6) reported in the
VEST trial. The difference in heart failure medication was
also investigated to identify reasons for the difference in
treatment incidence. The overall guideline-oriented heart
failure therapy, however, was established and optimised in
the vast majority of the total study population without rel-
evant differences among participating centres.
Although patients wearing the WCD for bridging had the
highest treatment incidence in our study population, these
patients have had an established indication for ICD im-
plantation based on previous publications and current
guidelines [4, 11–14], hence the term “bridging”. The ef-
ficacy of the WCD in this setting has previously been
demonstrated, albeit only within the frame of observational
studies [15, 16]. Although the largest subpopulation of pa-
tients with WCD therapy had NICM in the majority of
published observational trials including patients with any
indication for therapy [17–22], patients with ICM have
been shown to be at higher arrhythmogenic risk even in
the early post-myocardial infarction period [10]. In a large
observational study investigating patients with ICM using
a WCD, the incident-appropriate treatment rate was 7 per
100 persons over 3 months, and in the meta-analysis by
Masri et al. 8 per 100 persons over 3 months of follow-up
[8, 23]. Our findings were similar.
The only randomised controlled trial investigating WCD
use puts our data and previously published observational
studies in perspective. The VEST trial included patients
with ICM and reduced ejection fraction and investigated
whether WCD reduced the rate of sudden cardiac death
[24]. The primary endpoint was negative, and they report-
ed a low incident-appropriate treatment rate in the WCD
arm (1 per 100 persons over 3 months). This treatment in-
cidence was lower than had previously been reported from
observational data and what we found for our population.
One major difference between the VEST trial and existing
observational data, including this study, is the adherence
to therapy. Whereas “real-world” data have consistently
shown a high compliance with WCD use [8], Olgin et al.
reported a very low adherence to therapy with a mean dai-
ly wear-time of the WCD of 14 hours. Furthermore, 5.9%
of screened patients died in the VEST trial before inclusion
[24], similar to what was reported in the CARISMA study
(6.4%), in which the prognostic relevance of arrhythmias
in patients with ICM was investigated [25]. These patients
most probably might have benefited most from wearing
the WCD. On the other hand, the non-significant reduction
in sudden cardiac death in the VEST trial probably indi-
cates a competing, non-arrhythmic mortality rate in the in-
vestigated study population, similar to the DINAMIT trial
[26]. The neutral findings of the VEST trial ultimately do
not support routine use of WCD in patients suffering from
ICM with reduced EF.
In contrast to the higher treatment incidence in patients
suffering from ICM, we saw a lower treatment incidence
in patients with NICM in our study population. Only one
patient with NICM received a treatment reflecting an inci-
dent appropriate treatment rate of 1.2 per 100 persons over
3 months. In previous studies including only patients with
Table 4: Rate of implantable cardioverter defibrillator (ICD) insertion after wearable cardioverter defibrillator (WCD) use.
Hospital USZ USB KSW HUG KSSG Triemli CHUV KSA Inselspital GZO LUKS KSGR
ICD implanted 89 (46.4) 21 (48.8) 15 (39.5) 14 (42.4) 15 (55.6) 10 (38.5) 13 (59.1) 4 (19) 13 (65) 10 (66.7) 5 (38.5) 3 (50)
No ICD implant-
ed
– Not indicated 77 (40.1) 10 (23.3) 22 (57.9) 13 (39.4) 11 (40.7) 10 (38.5) 5 (22.7) 17 (81) 7 (35) 5 (33.3) 4 (30.8) 2 (33.3)
– Patient refusal 10 (5.2) 4 (9.3) 0 1 (3) 1 (3.7) 2 (7.6) 0 0 0 0 1 (7.7) 1 (16.7)
Other 14 (7.3) 7 (16.3) 1 (2.6) 5 (15.2) 0 4 (15.4) 3 (13.6) 0 0 0 3 (23) 0
– Lost to follow-
up
2 (1) 1 (2.3) 0 0 0 0 1 (4.6) 0 0 0 0 0
Other reasons included change of therapy to best supportive care, patient deceased, technical difficulties with implantation and unknown reasons. Results are reported as fre-
quencies (percentage).
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NICM this incidence was similar (1–8 per 100 persons per
3 months) [8, 27–29]. There is a controversy regarding
ICD indications for patients with NICM, which was further
fuelled by the DANISH trial [30]. A recent meta-analy-
sis, however, confirmed an overall benefit from ICD im-
plantation even when the results of the DANISH trial were
taken into account [31]. Probably because of the contro-
versy around ICD implantation in NICM, very long wear
durations have been reported in such patients. The pre-
sumed aim of prolonged WCD use was to avoid unneces-
sary ICD implantations. Although there have been reports
of a decreasing incidence of ICD implantation after pro-
longed WCD use, during which heart failure therapy was
optimised [27], the generally lower incidence of treatment
with the WCD makes patient selection difficult. Obvious-
ly, data to support a general recommendation of WCD use
for these individuals are lacking.
Similar to the high rate of optimal medical therapy of pa-
tients with reduced EF, WCD adherence was high in our
study population without any significant regional differ-
ences and an average daily wear-time of 22.6 hours, which
is similar to previous large observational data ranging from
21.7 to 23.1 hours [8, 16, 17, 22, 23]. The Swiss regula-
tory department responsible for medical devices (MiGeL)
generally reimburses 30–60 days of WCD wear duration
[3], and accordingly the median wear duration was 58 days
in the total study population which is comparable to previ-
ous findings [8]. However, 47% of patients wore the WCD
for longer than 60 days, and only two of these patients
received a treatment (0.9% of all patients with prolonged
WCD use). Kutyifa et al reported two patients out of 981
(0.2%) patients wearing the WCD >90 days receiving a
treatment compared with 19 out of 1019 patients wear-
ing the WCD ≤90 days [32]. Extended wear duration is
commonly reported, but the treatment rate beyond 90 days
of wear duration is very low [33]. These findings suggest
that WCD wear duration may be further shortened with-
out substantially compromising outcome. In our study pop-
ulation, median wear duration to a treatment was only 13
days in patients with ICM, in line with the findings of the
VALIANT trial, which observed an elevated risk during
the early post-myocardial infarction period [10]. Reduc-
tion in wear days could also lead to a significant reduction
in treatment costs. Current pricing according to MiGeL is
CHF 124 per day amounting to average costs per patient
of CHF 7200, calculated with the median wear duration
of 58 days. Nevertheless, independent of the cost of use,
if a WCD is prescribed, high wear-compliance is essential
to prevent a fatal outcome if ventricular arrhythmias arise
[34, 35]. The efficacy of the WCD in patients with high-
er compliance with therapy was additionally proven in a
recently published per protocol analysis of the VEST trial
[36].
The purpose of the WCD is to prevent sudden cardiac
death in patients at risk, but also to decrease the rate of un-
necessary ICD implantations, especially in the presence of
transient risk factors. We report an ICD implantation rate
of 47% after termination of WCD use. Previously, smaller
studies reported rates of between 32% and 55% [20, 27, 28,
37, 38]. The currently recruiting observational HF-Opt tri-
al (NCT03016754) is investigating the possible use of the
WCD to enable maximal up-titration of heart failure med-
ication to further reduce the ICD implantation rate. In ad-
dition to the prevention of possibly unnecessary ICD im-
plantations, this strategy may also be interesting in view of
cost-effectiveness. Until hard clinical endpoint data using
this approach are available, however, indications for ICD
implantation should follow current guidelines [4].
The major limitation of our study is its retrospective and
observational nature. Furthermore, the heterogeneity and
relatively small patient numbers limit the impact of com-
parative statistical analysis. Nevertheless, our data provide
useful real-life data on WCD use and efficacy in patients at
risk for sudden cardiac death in Switzerland.
Conclusions
In the reported study period, the use of WCD was in-
creasing in Switzerland with results comparable to previ-
ously published registry data. In light of the paucity of
randomised controlled data supporting its use, careful and
individualised patient selection is crucial, and standard op-
erating procedures at prescribing hospitals may be of val-
ue.
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Appendix 1 Supplementary table
Table S1: Comparison of patients with and without wearable cardioverter defibrillator treatment.
Treatment by WCD Yes No
Age at therapy start (years) 63 (11) 57 (14)
Sex (female) 2 (17) 79 (18)
BMI 27.7 (5.7) 26.8 (5.8)
Indication for WCD use
– ICM and LVEF <35% 8 (66.7) 198 (44.6)
– NICM and LVEF <35% 1 (8.3) 114 (25.7)
– Congenital or inherited heart disease 0 (0) 15 (3.4)
– Bridging to ICD implant or HTX 3 (25) 34 (7.7)
– Risk stratification with LVEF >35% 0 (0) 83 (18.7)
LVEF before WCD (%) 24 (5) 32 (13)
Atrial fibrillation 4 (33.3) 104 (23.4)
Wear days of WCD 26 (26) 69 (53)
Average wear hours of WCD 20.5 (3.6) 20.8 (4.2)
HTX = heart transplantation; ICM = ischaemic cardiomyopathy; LVEF = left ventricular ejection fraction; NICM = nonischaemic cardiomyopathy; WCD = wearable cardioverter
defibrillator Values are reported as mean (± standard deviation) or number (percentage).
Original article Swiss Med Wkly. 2020;150:w20343
Swiss Medical Weekly · PDF of the online version · www.smw.ch
Published under the copyright license “Attribution – Non-Commercial – No Derivatives 4.0”.
No commercial reuse without permission. See http://emh.ch/en/services/permissions.html.
Page 9 of 9
